- Ring The Bell
- Posts
- From Opaganib To Talicia, RedHill Biopharma’s Drugs Expanding Potential
From Opaganib To Talicia, RedHill Biopharma’s Drugs Expanding Potential
You're receiving this email because you're subscribed to Ring the Bell from Benzinga. To manage your subscription, click the link at the bottom of this email.
This message is from a valued third-party sponsor. It should not be considered a recommendation or endorsement by Benzinga.
A promising week for RedHill Biopharma Ltd. (NASDAQ: RDHL), a specialty biopharmaceutical company, who, together with partner Apogee Biotechnology Corp., unveiled a previously unexplored pathway for fighting diabetes and obesity-related disorders with its pipeline drug, opaganib, showing promise for the potential prevention and treatment of diabetes and other obesity-related disorders. They also announced the launch of Talicia, its drug to treat Helicobacter pylori (H. pylori) infection, in the United Arab Emirates, adding to its primary market in the U.S.
Take opaganib, RedHill Biopharma’s first-in-class new chemical entity with anti-inflammatory, anti-cancer and antiviral activity for starters. The company recently announced positive results from in vivo studies conducted by its partner, Apogee.
The studies looked at the impact opaganib had on weight gain and glucose tolerance in a high-fat diet (HFD) model. They demonstrated opaganib suppressed HFD-induced body weight gain, loss of glucose tolerance and fat deposition. Additionally, opaganib reduced weight gain and restored glucose tolerance in an already obese HFD model, suggesting its potential for treating, not just preventing, obesity-related disorders, reports RedHill Biopharma. With a market opportunity that’s projected to hit $100 billion by 2034, Redhill has a big opportunity with opaganib to treat and prevent diabetes and other obesity-related diseases.
Then there is H. pylori and RedHill Biopharma’s drug Talicia - which has just been launched in the UAE. Talicia, which the Company also markets in the U.S., is the first approved low-dose rifabutin-containing all-in-one combination product in the UAE specifically designed to treat H. pylori, a bacterial infection that affects more than 50% of the adult population. Commercial launch in the UAE triggers RedHill’s eligibility for additional potential milestone payments, minimum sales payments and tiered royalties up to mid-teens on net sales.